Literature DB >> 26124775

Prevalence of hepatitis B and C and relationship to liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic (JCRC), Kampala, Uganda.

Joy Baseke1, Monica Musenero2, Harriet Mayanja-Kizza3.   

Abstract

BACKGROUND: Hepatitis B and C viruses cause death due to liver disease worldwide among Human Immunodeficiency Virus (HIV) positive individuals. Hepatitis B (HBV) and HIV have similar routes of transmission primarily; sexual, intravenous injections and prenatal while hepatitis C (HCV) is transmitted mainly through blood transfusion. Human immunodeficiency virus increases the pathological effect of hepatitis viruses and potentiates re-activation of latent hepatitis infections as a result of reduced immunity. The increase in use of antiretroviral (ARVs) drugs has led to longer period for patient survival and apparent increase in liver disease among HIV positive individuals.
OBJECTIVE: This study aimed at determining the prevalence of HBV, HCV, their co-infection with HIV and their effect on liver cell function.
METHOD: This was a cross sectional study conducted at the Joint Clinical Research Centre (JCRC) among HIV positive individuals attending the clinic. Patients were enrolled after obtaining a signed informed consent or assent for children below 17 years. Serum samples were collected for detection of Hepatitis B surface antigen (HBsAg), HCV specific antibodies and alanine aminotransferase (ALT) liver enzyme.
RESULTS: Of the 89 patients enrolled, 20 (22.5%) had at least one hepatitis virus, 15 tested positive for HBsAg (16.9%) and 5 for HCV (5.6%), one had both viruses. Hepatitis B was more prevalent among women (13 out of 57, 22.8%) than men, (2 out of 32, 6.2%), while HCV was higher among men (4 out of 32, 12.5%) than women (1 out of 57, 1.8%). Seven of 89 patients (7.9%) had elevated ALT, indicative of liver cell injury. Of these with liver cell injury, one individual tested positive for HBsAg and another one individual tested positive for HCV specific antibodies.
CONCLUSION: The prevalence of HBV is high in HIV positive individuals with more women commonly infected. The Prevalence of HCV is lower than that of HBV with more men commonly infected. Co-infection of Hepatitis B and C viruses was uncommon. This study reveals a high prevalence of liver cell injury among HIV positive individuals although the injury due to HBV or HCV infection was lower than that which has been documented. From this study, the high prevalence of HBV and HCV among HIV positive individuals point to a need for screening of HIV positive individuals for the hepatitis viruses.

Entities:  

Keywords:  HBV surface antigen; HIV; Hepatitis B virus; Hepatitis C virus; Hepatitis C virus antibodies; Liver damage

Mesh:

Substances:

Year:  2015        PMID: 26124775      PMCID: PMC4480486          DOI: 10.4314/ahs.v15i2.3

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  11 in total

1.  Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda.

Authors:  P Ocama; B Castelnuovo; M R Kamya; G D Kirk; S J Reynolds; A Kiragga; R Colebunders; D L Thomas
Journal:  Int J STD AIDS       Date:  2010-08       Impact factor: 1.359

2.  Prevalence and screening costs of hepatitis C virus among Ugandan blood donors.

Authors:  W Hladik; P Kataaha; J Mermin; M Purdy; G Otekat; E Lackritz; M J Alter; R Downing
Journal:  Trop Med Int Health       Date:  2006-06       Impact factor: 2.622

3.  Chronic hepatitis C is mild in menstruating women.

Authors:  M Sartori; S Andorno; C Rigamonti; E Grossini; G Nicosia; R Boldorini
Journal:  J Gastroenterol Hepatol       Date:  2000-12       Impact factor: 4.029

Review 4.  Epidemiology of viral hepatitis and HIV co-infection.

Authors:  Miriam J Alter
Journal:  J Hepatol       Date:  2005-11-21       Impact factor: 25.083

5.  Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey.

Authors:  Josephine Bwogi; Fiona Braka; Issa Makumbi; Vinod Mishra; Barnabas Bakamutumaho; Miriam Nanyunja; Alex Opio; Robert Downing; Benon Biryahwaho; Rosamund F Lewis
Journal:  Afr Health Sci       Date:  2009-06       Impact factor: 0.927

6.  Management of chronic hepatitis B and C in HIV-coinfected patients.

Authors:  Vincent Soriano; Pablo Barreiro; Marina Nuñez
Journal:  J Antimicrob Chemother       Date:  2006-03-23       Impact factor: 5.790

7.  Seroprevalence of anti-HCV and hepatitis B surface antigen in HIV infected patients.

Authors:  S S Tankhiwale; R K Khadase; S V Jalgoankar
Journal:  Indian J Med Microbiol       Date:  2003 Oct-Dec       Impact factor: 0.985

8.  Antiretroviral therapy and HIV/hepatitis B virus coinfection.

Authors:  Yves Benhamou
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

9.  The natural history of hepatitis C virus (HCV) infection.

Authors:  Stephen L Chen; Timothy R Morgan
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

10.  Molecular epidemiology of Hepatitis B virus genotypes in Pakistan.

Authors:  Muhammad Masroor Alam; Sohail Zahoor Zaidi; Salman Akbar Malik; Shahzad Shaukat; Asif Naeem; Salmaan Sharif; Mehar Angez; Javed Aslam Butt
Journal:  BMC Infect Dis       Date:  2007-10-08       Impact factor: 3.090

View more
  8 in total

1.  Infectious diseases and chronic care in Africa.

Authors:  James K Tumwine
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

2.  Prevalence of HIV and Its Co-Infection with Hepatitis B/C Virus Among Chronic Liver Disease Patients in Ethiopia.

Authors:  Yayehyirad Tassachew; Tamrat Abebe; Yeshambel Belyhun; Tezazu Teffera; Abate Bane Shewaye; Hailemichael Desalegn; Henok Andualem; Abiy Kinfu; Andargachew Mulu; Adane Mihret; Rawleigh Howe; Abraham Aseffa
Journal:  Hepat Med       Date:  2022-05-13

3.  Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda.

Authors:  E Seremba; J P Van Geertruyden; R Ssenyonga; C K Opio; J M Kaducu; J B Sempa; R Colebunders; P Ocama
Journal:  Vaccine       Date:  2017-04-20       Impact factor: 3.641

4.  Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda.

Authors:  E Seremba; P Ocama; R Ssekitoleko; H Mayanja-Kizza; S V Adams; J Orem; E Katabira; S J Reynolds; R Nabatanzi; C Casper; W Phipps
Journal:  Vaccine       Date:  2021-01-28       Impact factor: 3.641

5.  The prevalence of hepatitis B virus among HIV-positive patients at Kilimanjaro Christian Medical Centre Referral Hospital, Northern Tanzania.

Authors:  Tasilo Kamenya; Damian Jeremia Damian; James Samwel Ngocho; Rune Nathaniel Philemon; Michael Johnson Mahande; Sia Emmanueli Msuya
Journal:  Pan Afr Med J       Date:  2017-11-28

6.  Mapping the evidence of hepatoprotective properties of Moringa oleifera from sub-Saharan African countries: a systematic review protocol.

Authors:  Willy Tambwe Muzumbukilwa; Mukanda Gedeon Kadima; Manimbulu Nlooto; Peter Mark Oroma Owira
Journal:  Syst Rev       Date:  2019-08-08

7.  Hepatitis B & C virus infection in HIV seropositive individuals & their association with risk factors: A hospital-based study.

Authors:  Vineeta Sharma; V G Ramachandran; Narendra Singh Mogha; Mausumi Bharadwaj
Journal:  Indian J Med Res       Date:  2018-06       Impact factor: 2.375

8.  Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care.

Authors:  Faustina Pappoe; Charles Kofi Oheneba Hagan; Dorcas Obiri-Yeboah; Paul Nsiah
Journal:  BMC Infect Dis       Date:  2019-05-03       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.